1 / 12

Corneal crosslinking for the treatment of keratoconus: results in the initial 50 cases

Corneal crosslinking for the treatment of keratoconus: results in the initial 50 cases. Pierre Fournié, Jean-Louis Arné, François Malecaze Purpan Hospital, Toulouse, France. The authors acknowledge no financial interest. Treatment Procedure. 4. Apply Riboflavin: 1 drop every minute for 20 min.

melodie-black
Download Presentation

Corneal crosslinking for the treatment of keratoconus: results in the initial 50 cases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Corneal crosslinking for the treatment of keratoconus: results in the initial 50 cases Pierre Fournié, Jean-Louis Arné, François Malecaze Purpan Hospital, Toulouse, France The authors acknowledge no financial interest

  2. Treatment Procedure 4. Apply Riboflavin: 1 drop every minute for 20 min 1. Topography: progressive type of keratoconus >1D in 6-12 months >2D in 12-24 months 5. Slit lamp inspection (blue light) “yellow flare” 2. Pachymetry: Corneal thickness > 400 m 6. UVA (370nm) 3 mW/cm2 1 drop of Riboflavin every 2 min for 30 min 3. Partial epithelium removal 8-9 mm

  3. Preoperative Data

  4. Maximum K values (Kmax) p<.05

  5. Preop Differential map Post CXL 1 year

  6. BSCVA (Decimal) p<.05

  7. 6 months 41% improvement 34% stabilization + + + +

  8. Cylinder

  9. Pachymetry

  10. Endothelial Cell Count

  11. Ocular Response Analyzer p>.05

  12. Conclusions • In vitro studies show that riboflavin and UVA significantly stiffen the anterior 200-300 m of the cornea • In our series, Riboflavin/UVA collagen crosslinking appears to be an efficacious procedure in inhibiting the progression of irregular astigmatism due to keratoconus while • stabilizing (±1D in 61.1%) or reducing (at least 1D in 30.5%) the corneal curvature • and increasing BSCVA (at least 1 line in 41% of eyes) • ORA failed to demonstrate any statistically significant difference after CXL

More Related